BIOLOGIC THERAPY IN ATOPIC ECZEMA
Autor(a) principal: | |
---|---|
Data de Publicação: | 2014 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://doi.org/10.29021/spdv.72.1.228 |
Resumo: | Atopic eczema is a common inflammatory skin disease, affecting up to 20% of children and 3% of adults in industrialized countries. Most cases of atopic eczema are mild to moderate and will be adequately managed with topical therapy. Persistent or severe cases may require periods of systemic treatment, which can be broadly grouped into conventional and biologic agents. Conventional systemic agents are associated with potential toxicities that limit the continued use and often do not provide adequate therapeutic responses. More recently, biologic agents have been proposed for the treatment of severe atopic eczema, holding promise for a more targeted and less toxic approach. However, none of the biologics have been approved for atopic eczema therapy yet. At present, its off-label use is advisable only in severe atopic eczema refractory to conventional treatments. In this report, the authors comprehensively review the literature regarding the use of biologic therapy in severe EA. |
id |
RCAP_2161061b392ea421dc059e8770963e2c |
---|---|
oai_identifier_str |
oai:ojs.revista.spdv.com.pt:article/228 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
BIOLOGIC THERAPY IN ATOPIC ECZEMATERAPÊUTICA BIOLÓGICA NO ECZEMA ATÓPICODermatitisatopicAntibodiesmonoclonalBiological therapyInfliximabEtanerceptAdalimumabEfalizumabAlefaceptRituximabMepolizumabOmalizumabUstecinumabDermatite atópicaTerapêutica biológicaAnticorpos monoclonaisEtanerceptAdalimumabEfalizumabAlefaceptRituximabMepolizumabOmalizumabUstecinumabAtopic eczema is a common inflammatory skin disease, affecting up to 20% of children and 3% of adults in industrialized countries. Most cases of atopic eczema are mild to moderate and will be adequately managed with topical therapy. Persistent or severe cases may require periods of systemic treatment, which can be broadly grouped into conventional and biologic agents. Conventional systemic agents are associated with potential toxicities that limit the continued use and often do not provide adequate therapeutic responses. More recently, biologic agents have been proposed for the treatment of severe atopic eczema, holding promise for a more targeted and less toxic approach. However, none of the biologics have been approved for atopic eczema therapy yet. At present, its off-label use is advisable only in severe atopic eczema refractory to conventional treatments. In this report, the authors comprehensively review the literature regarding the use of biologic therapy in severe EA.O eczema atópico é uma dermatose inflamatória comum, que afecta até 20% das crianças e 3% dos adultos nos países industrializados. A maioria dos doentes apresenta doença ligeira a moderada que é eficazmente controlada com terapêutica tópica. Os casos graves ou persistentes podem requerer períodos de terapêutica sistémica, a qual pode ser agrupada em convencional e biológica. Os medicamentos sistémicos convencionais estão associados a toxicidade potencial que limita o seu uso continuado e frequentemente não fornecem respostas terapêuticas adequadas. Mais recentemente os biológicos foram propostos para o tratamento do eczema atópico grave, podendo constituir uma opção menos tóxica e mais dirigida ao mecanismo etiopatogénico. Contudo, até à data nenhum biológico foi aprovado para o tratamento do eczema atópico. A sua utilização off-label é recomendável apenas nas formas graves refractárias aos tratamentos convencionais. Apresenta-se uma revisão da literatura sobre a utilização da terapêutica biológica no eczema atópico grave.Sociedade Portuguesa de Dermatologia e Venereologia2014-07-17T00:00:00Zjournal articleinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://doi.org/10.29021/spdv.72.1.228oai:ojs.revista.spdv.com.pt:article/228Journal of the Portuguese Society of Dermatology and Venereology; Vol 72 No 1 (2014): Janeiro - Março; 87-99Revista da Sociedade Portuguesa de Dermatologia e Venereologia; v. 72 n. 1 (2014): Janeiro - Março; 87-992182-24092182-2395reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://revista.spdv.com.pt/index.php/spdv/article/view/228https://doi.org/10.29021/spdv.72.1.228https://revista.spdv.com.pt/index.php/spdv/article/view/228/210Sanches de Brito, HelenaTavares, ErmelindoParente, JoanaAranha, JoãoSilva, Maria Joãoinfo:eu-repo/semantics/openAccess2022-10-06T12:34:46Zoai:ojs.revista.spdv.com.pt:article/228Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:10:46.839800Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
BIOLOGIC THERAPY IN ATOPIC ECZEMA TERAPÊUTICA BIOLÓGICA NO ECZEMA ATÓPICO |
title |
BIOLOGIC THERAPY IN ATOPIC ECZEMA |
spellingShingle |
BIOLOGIC THERAPY IN ATOPIC ECZEMA Sanches de Brito, Helena Dermatitis atopic Antibodies monoclonal Biological therapy Infliximab Etanercept Adalimumab Efalizumab Alefacept Rituximab Mepolizumab Omalizumab Ustecinumab Dermatite atópica Terapêutica biológica Anticorpos monoclonais Etanercept Adalimumab Efalizumab Alefacept Rituximab Mepolizumab Omalizumab Ustecinumab |
title_short |
BIOLOGIC THERAPY IN ATOPIC ECZEMA |
title_full |
BIOLOGIC THERAPY IN ATOPIC ECZEMA |
title_fullStr |
BIOLOGIC THERAPY IN ATOPIC ECZEMA |
title_full_unstemmed |
BIOLOGIC THERAPY IN ATOPIC ECZEMA |
title_sort |
BIOLOGIC THERAPY IN ATOPIC ECZEMA |
author |
Sanches de Brito, Helena |
author_facet |
Sanches de Brito, Helena Tavares, Ermelindo Parente, Joana Aranha, João Silva, Maria João |
author_role |
author |
author2 |
Tavares, Ermelindo Parente, Joana Aranha, João Silva, Maria João |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Sanches de Brito, Helena Tavares, Ermelindo Parente, Joana Aranha, João Silva, Maria João |
dc.subject.por.fl_str_mv |
Dermatitis atopic Antibodies monoclonal Biological therapy Infliximab Etanercept Adalimumab Efalizumab Alefacept Rituximab Mepolizumab Omalizumab Ustecinumab Dermatite atópica Terapêutica biológica Anticorpos monoclonais Etanercept Adalimumab Efalizumab Alefacept Rituximab Mepolizumab Omalizumab Ustecinumab |
topic |
Dermatitis atopic Antibodies monoclonal Biological therapy Infliximab Etanercept Adalimumab Efalizumab Alefacept Rituximab Mepolizumab Omalizumab Ustecinumab Dermatite atópica Terapêutica biológica Anticorpos monoclonais Etanercept Adalimumab Efalizumab Alefacept Rituximab Mepolizumab Omalizumab Ustecinumab |
description |
Atopic eczema is a common inflammatory skin disease, affecting up to 20% of children and 3% of adults in industrialized countries. Most cases of atopic eczema are mild to moderate and will be adequately managed with topical therapy. Persistent or severe cases may require periods of systemic treatment, which can be broadly grouped into conventional and biologic agents. Conventional systemic agents are associated with potential toxicities that limit the continued use and often do not provide adequate therapeutic responses. More recently, biologic agents have been proposed for the treatment of severe atopic eczema, holding promise for a more targeted and less toxic approach. However, none of the biologics have been approved for atopic eczema therapy yet. At present, its off-label use is advisable only in severe atopic eczema refractory to conventional treatments. In this report, the authors comprehensively review the literature regarding the use of biologic therapy in severe EA. |
publishDate |
2014 |
dc.date.none.fl_str_mv |
2014-07-17T00:00:00Z |
dc.type.driver.fl_str_mv |
journal article info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.29021/spdv.72.1.228 oai:ojs.revista.spdv.com.pt:article/228 |
url |
https://doi.org/10.29021/spdv.72.1.228 |
identifier_str_mv |
oai:ojs.revista.spdv.com.pt:article/228 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://revista.spdv.com.pt/index.php/spdv/article/view/228 https://doi.org/10.29021/spdv.72.1.228 https://revista.spdv.com.pt/index.php/spdv/article/view/228/210 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Sociedade Portuguesa de Dermatologia e Venereologia |
publisher.none.fl_str_mv |
Sociedade Portuguesa de Dermatologia e Venereologia |
dc.source.none.fl_str_mv |
Journal of the Portuguese Society of Dermatology and Venereology; Vol 72 No 1 (2014): Janeiro - Março; 87-99 Revista da Sociedade Portuguesa de Dermatologia e Venereologia; v. 72 n. 1 (2014): Janeiro - Março; 87-99 2182-2409 2182-2395 reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799130564251353088 |